



Free or Nanoformulated Forms of Novel Protease Inhibitors for Cancer Therapy

Guest Editor:

**Dr. Maria Francesca
Armentano**

Department of Scienze,
University of Basilicata, Viale
dell'Ateneo Lucano 10, 85100
Potenza, Italy

Deadline for manuscript
submissions:

closed (20 January 2024)

Message from the Guest Editor

Dear Colleagues,

Many studies indicate that intracellular proteases often participate in tumor growth and progression, being involved in important biological processes such as immune and inflammatory responses, angiogenesis, proliferation, epithelial-to-mesenchymal transition (EMT) and many others. Among the anticancer strategies, the antagonization of protease activity with increasingly effective molecules is certainly an encouraging therapeutic approach, especially if formulated in nanoparticle-based delivery systems that can increase bioavailability and circulation time and allow for accumulation—specifically in tumor tissues.

This Special Issue aims to establish a collection of papers to provide cutting-edge insight into all interested in this area of research. We welcome papers in the form of full research papers or focused reviews on some aspects of the theme.

I look forward to receiving your contributions.

Dr. Maria Francesca Armentano
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma